Gilead Sciences, Inc. (NASDAQ: GILD) reported total revenue of $6.6 billion for the second quarter of 2023, which was up 5% year-over-year.
Net income attributable to Gilead was $1 billion, or $0.83 per share, compared to $1.1 billion, or $0.91 per share, last year. Adjusted EPS was $1.34.
For the full year of 2023, GAAP EPS is expected to be $4.50-4.85 while adjusted EPS is estimated to be $6.45-6.80.
Prior performance
Most Popular
Intensity Therapeutics is establishing a new field of localized cancer reduction: CEO
Intensity Therapeutics, Inc. (NASDAQ: INTS) is a clinical biotechnology company engaged in the discovery development, and commercialization of first-in-class cancer drugs that attenuate tumors with minimal side effects while training
What to expect when J.M. Smucker (SJM) reports Q2 2025 earnings results
Shares of The J.M. Smucker Co. (NYSE: SJM) stayed red on Friday. The stock has dropped 6% over the past three months. The branded foods company is slated to report
Earnings Summary: Highlights of BJ’s Wholesale Club’s Q3 2024 results
Department store chain BJ’s Wholesale Club Holdings, Inc. (NYSE: BJ) has reported financial results for the third quarter of 2024, reporting a 3% increase in net sales. Adjusted earnings, on a
